logo
Share SHARE
FONT-SIZE Plus   Neg

Ind-Swift Labs Gets US FDA Nod For 5 APIs For Its Derabassi Facility

Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.

The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).

With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.

The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.

Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."

At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Major League Baseball is talking expansion for the first time in a few decades. Owners stand to make a pretty penny from expansion fees and subsequent television rights. The possibility of a more balanced schedule is also enticing. Strong expansion candidates in the U.S. and Canada are ready... The New York Times is teaming up with Google again to give away Google Cardboard, the virtual reality headsets, but this time only to its "most loyal" digital subscribers. The company said that the digital-only subscribers selected for this distribution were chosen based on the duration of their subscriptions. Oil company Exxon Mobil Corp. on Friday reported a 63 percent fall in profit for the first quarter from last year, while Chevron Corp. reported a loss for the quarter, both on lower revenues. The results were impacted by the fall in crude oil prices and weaker refining margins. However, Exxon Mobil's earnings beat analysts' estimates, while Chevron's loss was wider than their expectations.
comments powered by Disqus
Follow RTT